9/15/2009

Salix Pharmaceuticals' rifaximin, a drug for traveler's diarrhea, proved significantly more effective than placebo in treating nonconstipation irritable bowel syndrome and IBS-related bloating during two late-stage trials. Salix plans to seek FDA approval to promote rifaximin for IBS.

Related Summaries